Roche has been charting promising numbers for its standout breast cancer drugs Kadcyla and Perjeta. But now the next-gen duo has failed to beat Herceptin and chemo in a late-stage study, putting a damper on Roche's plan to expand the market for its new drugs and sending its shares into a downward spiral.
Novartis' Afinitor already boasts an indication in advanced HR-positive, HER2-negative breast cancer, and the pharma giant was hoping to double up by adding a nod for HER2-positive advanced breast cancer. But no such luck: On Friday, the drugmaker announced its treatment had come up short in a Phase III trial.
Roche can thank its newly augmented breast cancer portfolio for powering third-quarter sales upward, far enough to surpass analyst estimates. And given the latest data on one of those drugs--Perjeta--more growth could be at hand.
The National Institute for Health and Care Excellence has issued its final draft guidance for Kadcyla, which declares the drug is too expensive to cover.
Researchers have developed a computational cancer model to predict how a drug will perform in humans, VentureBeat reports.
Now that the Pfizer takeover AstraZeneca fought to avoid is on the rocks--at least for the time being--the pressure's on the British drugmaker to deliver strong growth on its own. And while much of the attention is focused on its pipeline, leading cancer drug Zoladex may be able to chip in, too, with new data suggesting it could help prevent infertility in some breast cancer patients receiving chemo.
Glaxo announced at ASCO on Sunday that in a Phase III study, Tykerb and Herceptin failed to improve disease-free survival in HER2-positive early breast cancer patients over Herceptin on its own.
Roche will use its diagnostic test for Perjeta and Kadcyla to identify patients best suited for the treatments
It will allow doctors to spot patients who will benefit from those treatments.
The growing pool of genomics data and bioinformatics capabilities present new opportunities to improve outcomes for cancer patients. Yet without coordinated, multidisciplinary collaborations, the industry risks failing to take full advantage, researchers warned this week.
Perjeta is now the first cancer drug approved to treat patients before surgery. Developed by Roche's Genentech unit, and already approved for women with advanced HER2-positive breast cancer, Perjeta can now reach a huge new group of patients at early stages of the disease.